ValiRx Plc Stock London S.E.
Equities
GB00B23N9136
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
Apr. 22 | Valirx plc Announces Directorate Changes | CI |
Mar. 21 | ValiRx inks evaluation deal with Imperial College London for research | AN |
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 4.43M 5.57M |
---|---|---|---|---|---|
Net income 2023 * | -2M -2.51M | Net income 2024 * | - | EV / Sales 2023 * | - |
Net cash position 2023 * | 1.8M 2.26M | Net cash position 2024 * | - 0 | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.02
x | P/E ratio 2024 * |
-
| Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 83.27% |
Managers | Title | Age | Since |
---|---|---|---|
Suzanne Dilly
CEO | Chief Executive Officer | 46 | - |
Gerald Desler
DFI | Director of Finance/CFO | 79 | 06-08-31 |
Chief Tech/Sci/R&D Officer | - | 22-09-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerald Desler
DFI | Director of Finance/CFO | 79 | 06-08-31 |
Kevin Cox
CHM | Chairman | 65 | 20-06-25 |
Director/Board Member | 57 | Feb. 28 |
1st Jan change | Capi. | |
---|---|---|
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |